Notably, CLDN8 expression appears to positively correlate with androgen receptor (AR) status in breast tumors, and patients with concomitantly low CLDN8 and low AR expression have particularly unfavorable prognoses [20]. Here, CLDN8 is linked to breast neoplasm.